Dew - very good thoughts, thanks for summarizing them, I'll be giving them lots of consideration.
But there are counterpoints to each of them as well, I'll do my best later when I have time.
One last thought though... where would COR be right now had CX717 not had a clinical hold placed on it last year? A clinical hold which the company is very confident has been proven to be a post-mortem artifact? A decision which the neurological division of the FDA agreed with 100%... today's decision to reject the IND was from the psychology division.
It's like anything in life, the end result is what matters.
But had the clinical hold not happened, a clinical hold whose concerns have been answered, instead of concerns about the entire platform, COR would probably be an $8 stock with new trials in multiple indications under way.
Market Data 
Markets 
AI
